PDGFR-alpha Inhibitors
3 drugsAbout PDGFR-alpha
PDGFR-alpha is a receptor tyrosine kinase crucial for cell growth, differentiation, and survival. Activated by PDGFs, it initiates intracellular signaling cascades that regulate fundamental cellular processes.
PDGFR-alpha is a therapeutic target because of its role in cell proliferation, though there is currently no genetic evidence directly linking it to specific diseases.
PDGFR-alpha is targeted by one FDA-approved small molecule drug, STIVARGA (Bayer), which has three indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Hepatocellular with only 3 trials.
Top Drugs
Bayer is the only company with an approved drug targeting PDGFR-alpha.
The market is highly concentrated, indicating potential entry barriers or limited investment in this target.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDGFR-alpha, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation and competitive advantage.
Clinical Trials 293 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 77 | 52 | 10 | 14 | 84% |
| Phase 2 | 139 | 55 | 22 | 61 | 71% |
| Phase 3 | 66 | 46 | 8 | 12 | 85% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved PDGFR-alpha drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PDGFR-alpha. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2012 - 2012)
The first and only drug, STIVARGA, was approved in 2012.
The approval timeline shows no recent activity, suggesting a saturated market or challenges in developing new PDGFR-alpha inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 217 clinical trials targeting PDGFR-alpha.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities